Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
Immune checkpoint inhibitors (ICIs) have been proven to be beneficial in multiple advanced malignancies. However, the widespread use of ICIs also occurred with various immune-related adverse events (irAEs). Here, we first report a case of sintilimab-related cystitis/ureteritis. A 53-year-old man wit...
Main Authors: | Lingfang Tu, Yuan Ye, Xiaoping Tang, Zhen Liang, Qihan You, Jianying Zhou, Zhijie Pan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.757069/full |
Similar Items
-
Immune Thrombocytopenia Induced by Sintilimab in Lung Cancer:
A Case Report and Literature Review
by: Jingjing CAI, et al.
Published: (2023-09-01) -
Sintilimab-induced inflammatory myopathy in a patient with esophageal cancer: a case report
by: Guo Hong, et al.
Published: (2023-10-01) -
Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment
by: Baohui Hong, et al.
Published: (2024-02-01) -
Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis/cystitis and review of the literature
by: Qihao Zhou, et al.
Published: (2023-10-01) -
Case Report: Toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma
by: Huayu Yang, et al.
Published: (2022-12-01)